COPENHAGEN, Denmark, September 7 /PRNewswire/ --

- Summary: Genmab Announces ofatumumab Appeared More Effective Than
rituximab in a Pre-Clinical Study

Genmab A/S (OMX: GEN) announced today that ofatumumab (HuMax-CD20(R))
appeared more effective at inducing complement dependent cytotoxicity (CDC),
an immune system killing mechanism, than rituximab in a pre-clinical study.
The CD20 antibodies were incubated with tumor cells and analyzed using
Spinning Disk Confocal Fluorescent Microscopy. This technology allows imaging
of the effects on target cells induced by therapeutic antibodies in real
time. Both antibodies were found to activate CDC and induced profound changes
in both shape and appearance of target cells.

Direct comparisons of ofatumumab and rituximab revealed ofatumumab to
induce much more rapid and profound CDC and far more impressive cell changes
than rituximab. This, furthermore, lead to more effective killing of target
cells by ofatumumab.

"This study supports the growing body of pre-clinical research that
suggests ofatumumab may be more effective in eliminating target cells and
treating diseases such as lymphoid cancers and rheumatoid arthritis than
existing therapies," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of
Genmab.

These pre-clinical data will be presented in an oral presentation at the
XIth European Meeting on Complement in Human Disease, in Cardiff, United
Kingdom on September 9, 2007.

About Genmab A/S

Genmab is a leading international biotechnology company focused on
developing fully human antibody therapeutics for unmet medical needs. Using
unique, cutting-edge antibody technology, Genmab's world class discovery and
development teams have created and developed an extensive pipeline of
products for potential treatment of a variety of diseases including cancer
and autoimmune disorders. As Genmab advances towards a commercial future, we
remain committed to our primary goal of improving the lives of patients who
are in urgent need of new treatment options. For more information on Genmab's
products and technology, visit www.genmab.com.

This press release contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar
expressions identify forward looking statements. Actual results or
performance may differ materially from any future results or performance
expressed or implied by such statements. The important factors that could
cause our actual results or performance to differ materially include, among
others, risks associated with product discovery and development,
uncertainties related to the outcome and conduct of clinical trials including
unforeseen safety issues, uncertainties related to product manufacturing, the
lack of market acceptance of our products, our inability to manage growth,
the competitive environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab
is not under an obligation to up-date statements regarding the future
following the publication of this release; nor to confirm such statements in
relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R);
HuMax-CD20(R); HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM);
HuMax-HepC(TM); HuMax-CD38(TM); HuMax-ZP3(TM); and UniBody(TM) are all
trademarks of Genmab A/S.

Stock Exchange Release no. 37/2007